https://doi.org/10.1016/j.lanmic.2024.07.015
J
Julia Dreisbach
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
24
Papers
157
Citations
6
h-index
6
i10-index
Julia Dreisbach is an academic researcher from German Center for Infection Research. The author has contributed to research in topics: Tuberculosis Research and Epidemiology & Cancer therapeutics and mechanisms & Phenothiazines and Benzothiazines Synthesis and Activities. The author has an h-index of 6, co-authored 21 publications.
ORCID: 0000-0001-6625-9857Papers by this author
worksSafety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
2025 · The Lancet Microbe · 20 citations
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
2025 · The Lancet Microbe · 20 citations
https://doi.org/10.1016/j.lanmic.2024.07.015
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis
2025 · Nature Communications · 13 citations
https://doi.org/10.1038/s41467-025-56146-9
Kooperationsprojekt TTU 02.901 - BTZ043 - ein neues TB Medikament (Klinikum der Universität München)
2018 · Open MIND · 0 citations
"Zwanzig20 - InfectControl 2020 - Verbundvorhaben: BTZ043 - ein neues Tuberkulose-Antibiotikum: Identifizierung und Quantifizierung des Metabolitenspektrums - ein essentieller Baustein in der Medikamentenentwicklung; Teilvorhaben BTZ-Met-ID - TV2
2022 · Open MIND · 0 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat